The DOI matches its Crossref record.
Surface modification of endovascular stents with rosuvastatin and heparin-loaded biodegradable nanofibers by electrospinning
Abstract
This study describes the development of drug-loaded nanofibrous scaffolds as a nanocoating for endovascular stents for the local and sustained delivery of rosuvastatin (Ros) and heparin (Hep) to injured artery walls after endovascular procedures via the electrospinning process. PURPOSE: The proposed hybrid covered stents can promote re-endothelialization; improve endothelial function; reduce inflammatory reaction; inhibit neointimal hyperplasia of the injured artery wall, due to well-known pleiotropic actions of Ros; and prevent adverse events such as in-stent restenosis (ISR) and stent thrombosis (ST), through the antithrombotic action of Hep. METHODS: -dimethylacetamide (DMAc) and acetone-based solvents. The polymeric solution was electrospun (e-spun) into drug-loaded AC nanofibers onto three different commercially available stents (Co-Cr stent, Ni-Ti stent, and stainless steel stent), resulting in nonwoven matrices of submicron-sized fibers. Accordingly, Hep solution was further used for fibrous coating onto the engineered Ros-loaded stent. The functional encapsulation of Ros and Hep drugs into polymeric scaffolds further underwent physicochemical analysis. Morphological characterization took place via scanning electron microscopy (SEM) and atomic force microscopy (AFM) analyses, while scaffolds' wettability properties were obtained by contact angle (CA) measurements. RESULTS: The morphology of the drug-loaded AC nanofibers was smooth, with an average diameter of 200-800 nm, and after CA measurement, we concluded to the superhydrophobic nature of the engineered scaffolds. In vitro release rates of the pharmaceutical drugs were determined using a high-performance liquid chromatography assay, which showed that after the initial burst, drug release was controlled slowly by the degradation of the polymeric materials. CONCLUSION: These results imply that AC nanofibers encapsulated with Ros and Hep drugs have great potential in the development of endovascular grafts with anti-thrombogenic properties that can accelerate the re-endothelialization, reduce the neointimal hyperplasia and inflammatory reaction, and improve the endothelial function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“During the electrospinning process, most molecules of the drug are dispersed within the PLGA matrix; however, some of them may be located on the fiber surface and be responsible for the initial burst release (Hsu et al., 2016; Janjic et al., 2017).”
From Minocycline-loaded PLGA electrospun membrane prevents alveolar bone loss in experimental peridontitis (2020) · cites this paper as Janjic et al., 2017
In the citing paper
“After the initial burst, the pattern of drug release is controlled not only by the diffusion but also by the degradation of the matrix material (Hsu et al., 2016; Janjic et al., 2017).”
From Minocycline-loaded PLGA electrospun membrane prevents alveolar bone loss in experimental peridontitis (2020) · cites this paper as Janjic et al., 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Drug Delivery Applications of Core-Sheath Nanofibers Prepared by Coaxial Electrospinning: A Review
Pant, B., Park, M., & Park, S.-J. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11070305 · Cited by 431
Ma, Y., Song, J., Almassri, H. N. S., Zhang, D., Zhang, T., Cheng, Y., & Wu, X. (2020) · Drug Delivery · doi:10.1080/10717544.2019.1709921 · Cited by 51
Metadata
- Authors
- Janjic, M., Pappa, F., Karagkiozaki, V., Gitas, C., Ktenidis, K., & Logothetidis, S.
- ORCID
- Pappa, Fotini
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2017-08
- Volume
- Volume 12
- Pages
- 6343-6355
- ISSN
- 1178-2013
- Cited by
- 32
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.